I-Mab
I-Mab (IMAB) Stock Competitors & Peer Comparison
See (IMAB) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IMAB | $5.16 | +0.00% | 397.7M | -8.85 | -$0.55 | N/A |
| VRTX | $390.30 | +0.00% | 100.7B | 27.96 | $14.05 | N/A |
| REGN | $565.97 | +0.00% | 60.5B | 14.62 | $39.70 | +0.30% |
| ALNY | $442.73 | +0.00% | 58.8B | -181.01 | -$2.48 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $652.43 | +0.00% | 40B | 33.29 | $19.64 | N/A |
| BNTX | $112.70 | +0.00% | 27.3B | -67.98 | -$1.67 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.45 | +0.00% | 19.8B | -26.43 | -$1.01 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.7B | N/A | N/A | N/A |
Stock Comparison
IMAB vs VRTX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, VRTX has a market cap of 100.7B. Regarding current trading prices, IMAB is priced at $5.16, while VRTX trades at $390.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas VRTX's P/E ratio is 27.96. In terms of profitability, IMAB's ROE is -0.04%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, IMAB is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check VRTX's competition here
IMAB vs REGN Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, REGN has a market cap of 60.5B. Regarding current trading prices, IMAB is priced at $5.16, while REGN trades at $565.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas REGN's P/E ratio is 14.62. In terms of profitability, IMAB's ROE is -0.04%, compared to REGN's ROE of +0.15%. Regarding short-term risk, IMAB is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check REGN's competition here
IMAB vs ALNY Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ALNY has a market cap of 58.8B. Regarding current trading prices, IMAB is priced at $5.16, while ALNY trades at $442.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ALNY's P/E ratio is -181.01. In terms of profitability, IMAB's ROE is -0.04%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, IMAB is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ALNY's competition here
IMAB vs SGEN Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, IMAB is priced at $5.16, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas SGEN's P/E ratio is -57.19. In terms of profitability, IMAB's ROE is -0.04%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, IMAB is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check SGEN's competition here
IMAB vs ARGX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ARGX has a market cap of 40B. Regarding current trading prices, IMAB is priced at $5.16, while ARGX trades at $652.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ARGX's P/E ratio is 33.29. In terms of profitability, IMAB's ROE is -0.04%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, IMAB is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ARGX's competition here
IMAB vs BNTX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, BNTX has a market cap of 27.3B. Regarding current trading prices, IMAB is priced at $5.16, while BNTX trades at $112.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas BNTX's P/E ratio is -67.98. In terms of profitability, IMAB's ROE is -0.04%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, IMAB is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BNTX's competition here
IMAB vs BGNE Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, IMAB is priced at $5.16, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas BGNE's P/E ratio is -22.55. In terms of profitability, IMAB's ROE is -0.04%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, IMAB is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BGNE's competition here
IMAB vs SMMT Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, SMMT has a market cap of 19.8B. Regarding current trading prices, IMAB is priced at $5.16, while SMMT trades at $26.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas SMMT's P/E ratio is -26.43. In terms of profitability, IMAB's ROE is -0.04%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, IMAB is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check SMMT's competition here
IMAB vs DNA-WT Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, IMAB is priced at $5.16, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, IMAB's ROE is -0.04%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, IMAB is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check DNA-WT's competition here
IMAB vs INCY Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, INCY has a market cap of 17B. Regarding current trading prices, IMAB is priced at $5.16, while INCY trades at $86.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas INCY's P/E ratio is 20.55. In terms of profitability, IMAB's ROE is -0.04%, compared to INCY's ROE of +0.34%. Regarding short-term risk, IMAB is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check INCY's competition here
IMAB vs RPRX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, RPRX has a market cap of 15.7B. Regarding current trading prices, IMAB is priced at $5.16, while RPRX trades at $36.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas RPRX's P/E ratio is 15.87. In terms of profitability, IMAB's ROE is -0.04%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, IMAB is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RPRX's competition here
IMAB vs GMAB Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, GMAB has a market cap of 14.7B. Regarding current trading prices, IMAB is priced at $5.16, while GMAB trades at $22.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas GMAB's P/E ratio is 12.08. In terms of profitability, IMAB's ROE is -0.04%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, IMAB is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check GMAB's competition here
IMAB vs UTHR Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, UTHR has a market cap of 14.2B. Regarding current trading prices, IMAB is priced at $5.16, while UTHR trades at $312.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas UTHR's P/E ratio is 12.22. In terms of profitability, IMAB's ROE is -0.04%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, IMAB is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check UTHR's competition here
IMAB vs KRTX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, IMAB is priced at $5.16, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas KRTX's P/E ratio is -28.09. In terms of profitability, IMAB's ROE is -0.04%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, IMAB is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check KRTX's competition here
IMAB vs ASND Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ASND has a market cap of 12B. Regarding current trading prices, IMAB is priced at $5.16, while ASND trades at $192.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ASND's P/E ratio is -37.63. In terms of profitability, IMAB's ROE is -0.04%, compared to ASND's ROE of +1.91%. Regarding short-term risk, IMAB is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ASND's competition here
IMAB vs BMRN Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, IMAB is priced at $5.16, while BMRN trades at $58.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas BMRN's P/E ratio is 16.97. In terms of profitability, IMAB's ROE is -0.04%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, IMAB is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BMRN's competition here
IMAB vs MRNA Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MRNA has a market cap of 10.9B. Regarding current trading prices, IMAB is priced at $5.16, while MRNA trades at $26.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MRNA's P/E ratio is -3.73. In terms of profitability, IMAB's ROE is -0.04%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, IMAB is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MRNA's competition here
IMAB vs EXEL Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, EXEL has a market cap of 10.3B. Regarding current trading prices, IMAB is priced at $5.16, while EXEL trades at $38.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas EXEL's P/E ratio is 18.42. In terms of profitability, IMAB's ROE is -0.04%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, IMAB is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check EXEL's competition here
IMAB vs BBIO Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, BBIO has a market cap of 9.8B. Regarding current trading prices, IMAB is priced at $5.16, while BBIO trades at $51.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas BBIO's P/E ratio is -12.43. In terms of profitability, IMAB's ROE is -0.04%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, IMAB is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BBIO's competition here
IMAB vs RXDX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, IMAB is priced at $5.16, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas RXDX's P/E ratio is -56.47. In terms of profitability, IMAB's ROE is -0.04%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RXDX's competition here
IMAB vs VRNA Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, IMAB is priced at $5.16, while VRNA trades at $105.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas VRNA's P/E ratio is -101.22. In terms of profitability, IMAB's ROE is -0.04%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, IMAB is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check VRNA's competition here
IMAB vs IMGN Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, IMAB is priced at $5.16, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas IMGN's P/E ratio is -111.55. In terms of profitability, IMAB's ROE is -0.04%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, IMAB is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check IMGN's competition here
IMAB vs TECH Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, TECH has a market cap of 8.4B. Regarding current trading prices, IMAB is priced at $5.16, while TECH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas TECH's P/E ratio is 116.52. In terms of profitability, IMAB's ROE is -0.04%, compared to TECH's ROE of +0.06%. Regarding short-term risk, IMAB is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check TECH's competition here
IMAB vs BPMC Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, IMAB is priced at $5.16, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas BPMC's P/E ratio is -51.58. In terms of profitability, IMAB's ROE is -0.04%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, IMAB is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BPMC's competition here
IMAB vs MDGL Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MDGL has a market cap of 8.2B. Regarding current trading prices, IMAB is priced at $5.16, while MDGL trades at $371.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MDGL's P/E ratio is -29.21. In terms of profitability, IMAB's ROE is -0.04%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, IMAB is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MDGL's competition here
IMAB vs CERE Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, IMAB is priced at $5.16, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas CERE's P/E ratio is -16.47. In terms of profitability, IMAB's ROE is -0.04%, compared to CERE's ROE of -0.72%. Regarding short-term risk, IMAB is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CERE's competition here
IMAB vs ROIV Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ROIV has a market cap of 8.1B. Regarding current trading prices, IMAB is priced at $5.16, while ROIV trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ROIV's P/E ratio is -10.87. In terms of profitability, IMAB's ROE is -0.04%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, IMAB is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ROIV's competition here
IMAB vs HALO Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, HALO has a market cap of 7.9B. Regarding current trading prices, IMAB is priced at $5.16, while HALO trades at $65.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas HALO's P/E ratio is 15.39. In terms of profitability, IMAB's ROE is -0.04%, compared to HALO's ROE of +1.37%. Regarding short-term risk, IMAB is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check HALO's competition here
IMAB vs ROIVW Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, IMAB is priced at $5.16, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, IMAB's ROE is -0.04%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, IMAB is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ROIVW's competition here
IMAB vs CORT Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, CORT has a market cap of 7.6B. Regarding current trading prices, IMAB is priced at $5.16, while CORT trades at $72.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas CORT's P/E ratio is 64.06. In terms of profitability, IMAB's ROE is -0.04%, compared to CORT's ROE of +0.20%. Regarding short-term risk, IMAB is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CORT's competition here
IMAB vs JAZZ Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, JAZZ has a market cap of 7.1B. Regarding current trading prices, IMAB is priced at $5.16, while JAZZ trades at $116.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas JAZZ's P/E ratio is -16.87. In terms of profitability, IMAB's ROE is -0.04%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, IMAB is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check JAZZ's competition here
IMAB vs IONS Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, IONS has a market cap of 7B. Regarding current trading prices, IMAB is priced at $5.16, while IONS trades at $42.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas IONS's P/E ratio is -24.87. In terms of profitability, IMAB's ROE is -0.04%, compared to IONS's ROE of -0.45%. Regarding short-term risk, IMAB is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check IONS's competition here
IMAB vs RVMD Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, RVMD has a market cap of 6.8B. Regarding current trading prices, IMAB is priced at $5.16, while RVMD trades at $36.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas RVMD's P/E ratio is -8.04. In terms of profitability, IMAB's ROE is -0.04%, compared to RVMD's ROE of -0.39%. Regarding short-term risk, IMAB is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RVMD's competition here
IMAB vs RETA Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, IMAB is priced at $5.16, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas RETA's P/E ratio is -66.29. In terms of profitability, IMAB's ROE is -0.04%, compared to RETA's ROE of +0.47%. Regarding short-term risk, IMAB is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RETA's competition here
IMAB vs RYTM Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, RYTM has a market cap of 6.5B. Regarding current trading prices, IMAB is priced at $5.16, while RYTM trades at $96.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas RYTM's P/E ratio is -32.43. In terms of profitability, IMAB's ROE is -0.04%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, IMAB is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RYTM's competition here
IMAB vs RNA Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, RNA has a market cap of 6B. Regarding current trading prices, IMAB is priced at $5.16, while RNA trades at $46.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas RNA's P/E ratio is -13.05. In terms of profitability, IMAB's ROE is -0.04%, compared to RNA's ROE of -0.33%. Regarding short-term risk, IMAB is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RNA's competition here
IMAB vs ABCM Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, IMAB is priced at $5.16, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, IMAB's ROE is -0.04%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, IMAB is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ABCM's competition here
IMAB vs ISEE Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, IMAB is priced at $5.16, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ISEE's P/E ratio is -22.44. In terms of profitability, IMAB's ROE is -0.04%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, IMAB is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ISEE's competition here
IMAB vs NUVL Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, IMAB is priced at $5.16, while NUVL trades at $76.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas NUVL's P/E ratio is -15.46. In terms of profitability, IMAB's ROE is -0.04%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, IMAB is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check NUVL's competition here
IMAB vs AXSM Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, AXSM has a market cap of 5.4B. Regarding current trading prices, IMAB is priced at $5.16, while AXSM trades at $108.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas AXSM's P/E ratio is -21.58. In terms of profitability, IMAB's ROE is -0.04%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, IMAB is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check AXSM's competition here
IMAB vs CRSP Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, CRSP has a market cap of 5.4B. Regarding current trading prices, IMAB is priced at $5.16, while CRSP trades at $58.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas CRSP's P/E ratio is -11.06. In terms of profitability, IMAB's ROE is -0.04%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, IMAB is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CRSP's competition here
IMAB vs ABVX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ABVX has a market cap of 5.3B. Regarding current trading prices, IMAB is priced at $5.16, while ABVX trades at $69.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ABVX's P/E ratio is -20.60. In terms of profitability, IMAB's ROE is -0.04%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, IMAB is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ABVX's competition here
IMAB vs MRUS Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MRUS has a market cap of 5.1B. Regarding current trading prices, IMAB is priced at $5.16, while MRUS trades at $66.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MRUS's P/E ratio is -12.05. In terms of profitability, IMAB's ROE is -0.04%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, IMAB is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MRUS's competition here
IMAB vs ALKS Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ALKS has a market cap of 4.8B. Regarding current trading prices, IMAB is priced at $5.16, while ALKS trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ALKS's P/E ratio is 14.03. In terms of profitability, IMAB's ROE is -0.04%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, IMAB is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ALKS's competition here
IMAB vs CYTK Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, CYTK has a market cap of 4.6B. Regarding current trading prices, IMAB is priced at $5.16, while CYTK trades at $38.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas CYTK's P/E ratio is -7.55. In terms of profitability, IMAB's ROE is -0.04%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, IMAB is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CYTK's competition here
IMAB vs VKTX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, VKTX has a market cap of 4.5B. Regarding current trading prices, IMAB is priced at $5.16, while VKTX trades at $40.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas VKTX's P/E ratio is -25.99. In terms of profitability, IMAB's ROE is -0.04%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, IMAB is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check VKTX's competition here
IMAB vs ALPN Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, IMAB is priced at $5.16, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ALPN's P/E ratio is -101.52. In terms of profitability, IMAB's ROE is -0.04%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, IMAB is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ALPN's competition here
IMAB vs TGTX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, TGTX has a market cap of 4.5B. Regarding current trading prices, IMAB is priced at $5.16, while TGTX trades at $27.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas TGTX's P/E ratio is 73.89. In terms of profitability, IMAB's ROE is -0.04%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, IMAB is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check TGTX's competition here
IMAB vs KRYS Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, IMAB is priced at $5.16, while KRYS trades at $150.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas KRYS's P/E ratio is 30.60. In terms of profitability, IMAB's ROE is -0.04%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, IMAB is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check KRYS's competition here
IMAB vs ACAD Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, IMAB is priced at $5.16, while ACAD trades at $24.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ACAD's P/E ratio is 19.05. In terms of profitability, IMAB's ROE is -0.04%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, IMAB is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ACAD's competition here
IMAB vs PCVX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, IMAB is priced at $5.16, while PCVX trades at $31.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas PCVX's P/E ratio is -7.96. In terms of profitability, IMAB's ROE is -0.04%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, IMAB is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check PCVX's competition here
IMAB vs OPT Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, IMAB is priced at $5.16, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas OPT's P/E ratio is -1.52. In terms of profitability, IMAB's ROE is -0.04%, compared to OPT's ROE of +2.60%. Regarding short-term risk, IMAB is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check OPT's competition here
IMAB vs AAPG Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, AAPG has a market cap of 4.1B. Regarding current trading prices, IMAB is priced at $5.16, while AAPG trades at $42.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas AAPG's P/E ratio is -60.54. In terms of profitability, IMAB's ROE is -0.04%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, IMAB is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check AAPG's competition here
IMAB vs MRTX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, IMAB is priced at $5.16, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MRTX's P/E ratio is -4.82. In terms of profitability, IMAB's ROE is -0.04%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, IMAB is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MRTX's competition here
IMAB vs ACLX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ACLX has a market cap of 4.1B. Regarding current trading prices, IMAB is priced at $5.16, while ACLX trades at $71.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ACLX's P/E ratio is -21.67. In terms of profitability, IMAB's ROE is -0.04%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, IMAB is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ACLX's competition here
IMAB vs ADMA Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, IMAB is priced at $5.16, while ADMA trades at $16.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ADMA's P/E ratio is 19.99. In terms of profitability, IMAB's ROE is -0.04%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, IMAB is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ADMA's competition here
IMAB vs AKRO Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, IMAB is priced at $5.16, while AKRO trades at $50.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas AKRO's P/E ratio is -12.96. In terms of profitability, IMAB's ROE is -0.04%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, IMAB is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check AKRO's competition here
IMAB vs ZLAB Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ZLAB has a market cap of 3.9B. Regarding current trading prices, IMAB is priced at $5.16, while ZLAB trades at $34.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ZLAB's P/E ratio is -17.86. In terms of profitability, IMAB's ROE is -0.04%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, IMAB is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ZLAB's competition here
IMAB vs TLX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, TLX has a market cap of 3.9B. Regarding current trading prices, IMAB is priced at $5.16, while TLX trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas TLX's P/E ratio is 128.22. In terms of profitability, IMAB's ROE is -0.04%, compared to TLX's ROE of +0.10%. Regarding short-term risk, IMAB is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check TLX's competition here
IMAB vs PTCT Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, PTCT has a market cap of 3.9B. Regarding current trading prices, IMAB is priced at $5.16, while PTCT trades at $48.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas PTCT's P/E ratio is 6.92. In terms of profitability, IMAB's ROE is -0.04%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, IMAB is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check PTCT's competition here
IMAB vs SLNO Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, SLNO has a market cap of 3.8B. Regarding current trading prices, IMAB is priced at $5.16, while SLNO trades at $77.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas SLNO's P/E ratio is -16.97. In terms of profitability, IMAB's ROE is -0.04%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, IMAB is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check SLNO's competition here
IMAB vs RYZB Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, IMAB is priced at $5.16, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas RYZB's P/E ratio is -57.86. In terms of profitability, IMAB's ROE is -0.04%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, IMAB is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RYZB's competition here
IMAB vs CBAY Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, IMAB is priced at $5.16, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas CBAY's P/E ratio is -32.81. In terms of profitability, IMAB's ROE is -0.04%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, IMAB is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CBAY's competition here
IMAB vs SWTX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, IMAB is priced at $5.16, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas SWTX's P/E ratio is -13.78. In terms of profitability, IMAB's ROE is -0.04%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, IMAB is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check SWTX's competition here
IMAB vs APLS Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, IMAB is priced at $5.16, while APLS trades at $27.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas APLS's P/E ratio is -15.16. In terms of profitability, IMAB's ROE is -0.04%, compared to APLS's ROE of -1.16%. Regarding short-term risk, IMAB is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check APLS's competition here
IMAB vs PTGX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, PTGX has a market cap of 3.5B. Regarding current trading prices, IMAB is priced at $5.16, while PTGX trades at $54.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas PTGX's P/E ratio is 76.81. In terms of profitability, IMAB's ROE is -0.04%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, IMAB is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check PTGX's competition here
IMAB vs MLTX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, IMAB is priced at $5.16, while MLTX trades at $54.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MLTX's P/E ratio is -19.49. In terms of profitability, IMAB's ROE is -0.04%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, IMAB is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MLTX's competition here
IMAB vs LEGN Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, LEGN has a market cap of 3.4B. Regarding current trading prices, IMAB is priced at $5.16, while LEGN trades at $37.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas LEGN's P/E ratio is -21.07. In terms of profitability, IMAB's ROE is -0.04%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, IMAB is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check LEGN's competition here
IMAB vs MIRM Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MIRM has a market cap of 3.4B. Regarding current trading prices, IMAB is priced at $5.16, while MIRM trades at $64.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MIRM's P/E ratio is -56.14. In terms of profitability, IMAB's ROE is -0.04%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, IMAB is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MIRM's competition here
IMAB vs MTSR Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MTSR has a market cap of 3.3B. Regarding current trading prices, IMAB is priced at $5.16, while MTSR trades at $30.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MTSR's P/E ratio is -10.59. In terms of profitability, IMAB's ROE is -0.04%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, IMAB is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MTSR's competition here
IMAB vs KYMR Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, IMAB is priced at $5.16, while KYMR trades at $41.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas KYMR's P/E ratio is -12.21. In terms of profitability, IMAB's ROE is -0.04%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, IMAB is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check KYMR's competition here
IMAB vs SRRK Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, SRRK has a market cap of 3B. Regarding current trading prices, IMAB is priced at $5.16, while SRRK trades at $32.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas SRRK's P/E ratio is -10.76. In terms of profitability, IMAB's ROE is -0.04%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, IMAB is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check SRRK's competition here
IMAB vs LGND Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, LGND has a market cap of 3B. Regarding current trading prices, IMAB is priced at $5.16, while LGND trades at $153.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas LGND's P/E ratio is -37.40. In terms of profitability, IMAB's ROE is -0.04%, compared to LGND's ROE of -0.09%. Regarding short-term risk, IMAB is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check LGND's competition here
IMAB vs XENE Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, XENE has a market cap of 2.9B. Regarding current trading prices, IMAB is priced at $5.16, while XENE trades at $37.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas XENE's P/E ratio is -10.77. In terms of profitability, IMAB's ROE is -0.04%, compared to XENE's ROE of -0.32%. Regarding short-term risk, IMAB is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check XENE's competition here
IMAB vs CRNX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, IMAB is priced at $5.16, while CRNX trades at $29.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas CRNX's P/E ratio is -7.49. In terms of profitability, IMAB's ROE is -0.04%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, IMAB is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CRNX's competition here
IMAB vs MORF Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, IMAB is priced at $5.16, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MORF's P/E ratio is -14.88. In terms of profitability, IMAB's ROE is -0.04%, compared to MORF's ROE of -0.16%. Regarding short-term risk, IMAB is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MORF's competition here
IMAB vs RARE Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, RARE has a market cap of 2.9B. Regarding current trading prices, IMAB is priced at $5.16, while RARE trades at $29.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas RARE's P/E ratio is -5.42. In terms of profitability, IMAB's ROE is -0.04%, compared to RARE's ROE of -2.37%. Regarding short-term risk, IMAB is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RARE's competition here
IMAB vs MOR Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, IMAB is priced at $5.16, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MOR's P/E ratio is -12.64. In terms of profitability, IMAB's ROE is -0.04%, compared to MOR's ROE of -1.84%. Regarding short-term risk, IMAB is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MOR's competition here
IMAB vs ARWR Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, ARWR has a market cap of 2.8B. Regarding current trading prices, IMAB is priced at $5.16, while ARWR trades at $18.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas ARWR's P/E ratio is -17.09. In terms of profitability, IMAB's ROE is -0.04%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, IMAB is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check ARWR's competition here
IMAB vs NAMS Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, IMAB is priced at $5.16, while NAMS trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas NAMS's P/E ratio is -15.77. In terms of profitability, IMAB's ROE is -0.04%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, IMAB is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check NAMS's competition here
IMAB vs KDNY Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, IMAB is priced at $5.16, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas KDNY's P/E ratio is -12.47. In terms of profitability, IMAB's ROE is -0.04%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, IMAB is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check KDNY's competition here
IMAB vs IMVT Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, IMAB is priced at $5.16, while IMVT trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas IMVT's P/E ratio is -5.36. In terms of profitability, IMAB's ROE is -0.04%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, IMAB is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check IMVT's competition here
IMAB vs MYOV Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, IMAB is priced at $5.16, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas MYOV's P/E ratio is -14.05. In terms of profitability, IMAB's ROE is -0.04%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, IMAB is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check MYOV's competition here
IMAB vs CPRX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, CPRX has a market cap of 2.5B. Regarding current trading prices, IMAB is priced at $5.16, while CPRX trades at $20.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas CPRX's P/E ratio is 12.26. In terms of profitability, IMAB's ROE is -0.04%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, IMAB is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CPRX's competition here
IMAB vs KNSA Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, IMAB is priced at $5.16, while KNSA trades at $33.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas KNSA's P/E ratio is 667.60. In terms of profitability, IMAB's ROE is -0.04%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, IMAB is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check KNSA's competition here
IMAB vs RXRX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, RXRX has a market cap of 2.5B. Regarding current trading prices, IMAB is priced at $5.16, while RXRX trades at $5.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas RXRX's P/E ratio is -3.19. In terms of profitability, IMAB's ROE is -0.04%, compared to RXRX's ROE of -0.76%. Regarding short-term risk, IMAB is more volatile compared to RXRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check RXRX's competition here
IMAB vs CNTA Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, CNTA has a market cap of 2.4B. Regarding current trading prices, IMAB is priced at $5.16, while CNTA trades at $17.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas CNTA's P/E ratio is -9.76. In terms of profitability, IMAB's ROE is -0.04%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, IMAB is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check CNTA's competition here
IMAB vs IBRX Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, IMAB is priced at $5.16, while IBRX trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas IBRX's P/E ratio is -5.31. In terms of profitability, IMAB's ROE is -0.04%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, IMAB is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check IBRX's competition here
IMAB vs VCYT Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, VCYT has a market cap of 2.4B. Regarding current trading prices, IMAB is priced at $5.16, while VCYT trades at $30.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas VCYT's P/E ratio is 88.88. In terms of profitability, IMAB's ROE is -0.04%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, IMAB is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check VCYT's competition here
IMAB vs PRVB Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, IMAB is priced at $5.16, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas PRVB's P/E ratio is -16.43. In terms of profitability, IMAB's ROE is -0.04%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, IMAB is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check PRVB's competition here
IMAB vs LBPH Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, IMAB is priced at $5.16, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas LBPH's P/E ratio is -26.66. In terms of profitability, IMAB's ROE is -0.04%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, IMAB is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check LBPH's competition here
IMAB vs TARS Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, TARS has a market cap of 2.3B. Regarding current trading prices, IMAB is priced at $5.16, while TARS trades at $54.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas TARS's P/E ratio is -23.67. In terms of profitability, IMAB's ROE is -0.04%, compared to TARS's ROE of -0.32%. Regarding short-term risk, IMAB is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check TARS's competition here
IMAB vs FOLD Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, FOLD has a market cap of 2.3B. Regarding current trading prices, IMAB is priced at $5.16, while FOLD trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas FOLD's P/E ratio is -61.67. In terms of profitability, IMAB's ROE is -0.04%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, IMAB is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check FOLD's competition here
IMAB vs DICE Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, IMAB is priced at $5.16, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas DICE's P/E ratio is -21.91. In terms of profitability, IMAB's ROE is -0.04%, compared to DICE's ROE of +0.56%. Regarding short-term risk, IMAB is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check DICE's competition here
IMAB vs LQDA Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, LQDA has a market cap of 2.2B. Regarding current trading prices, IMAB is priced at $5.16, while LQDA trades at $26.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas LQDA's P/E ratio is -14.26. In terms of profitability, IMAB's ROE is -0.04%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, IMAB is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check LQDA's competition here
IMAB vs APGE Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, IMAB is priced at $5.16, while APGE trades at $38.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas APGE's P/E ratio is -9.01. In terms of profitability, IMAB's ROE is -0.04%, compared to APGE's ROE of -0.23%. Regarding short-term risk, IMAB is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check APGE's competition here
IMAB vs OCUL Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, OCUL has a market cap of 2.2B. Regarding current trading prices, IMAB is priced at $5.16, while OCUL trades at $12.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas OCUL's P/E ratio is -10.02. In terms of profitability, IMAB's ROE is -0.04%, compared to OCUL's ROE of -0.70%. Regarding short-term risk, IMAB is more volatile compared to OCUL. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check OCUL's competition here
IMAB vs BLTE Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, BLTE has a market cap of 2.2B. Regarding current trading prices, IMAB is priced at $5.16, while BLTE trades at $68.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas BLTE's P/E ratio is -42.99. In terms of profitability, IMAB's ROE is -0.04%, compared to BLTE's ROE of -0.37%. Regarding short-term risk, IMAB is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check BLTE's competition here
IMAB vs AGIO Comparison August 2025
IMAB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMAB stands at 397.7M. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, IMAB is priced at $5.16, while AGIO trades at $36.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMAB currently has a P/E ratio of -8.85, whereas AGIO's P/E ratio is 3.28. In terms of profitability, IMAB's ROE is -0.04%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, IMAB is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for IMAB.Check AGIO's competition here